Dr. Anne-Marie Mes-Masson trained as a molecular oncologist and obtained her PhD from the Department of Microbiology and Immunology at McGill University in 1984. From 1984-1986, she completed post-doctoral studies at the Molecular Biology Institute, University of California Los Angeles. After a short period as a research associate at the Biotechnology Research Institute, Mes-Masson joined the Institut du cancer de Montréal and the Department of Medicine at the Université de Montréal in 1989. A full professor since 2001, Mes-Masson was the scientific director of the Institut du cancer de Montréal and Director of cancer research at the Centre de recherche du Centre hospitalier de l’université de Montréal (CRCHUM) from 2003-2018 and in 2017 accepted the position of Associate Director, Basic and Translational Research, at the CRCHUM. In 2003, Mes-Masson was named the Director of the Réseau de recherche sur le cancer du Fonds de recherche du Québec – Santé (FRQS), a provincial cancer network of more than 200 scientists focused on translational and clinical cancer research (www.rrcancer.ca) and she will complete her mandate in 2023. Mes-Masson is a founding member of the Canadian Tumour Repository Network that focuses on enhancing the capacity and quality of biobanking to support research (www.ctrnet.ca). Mes-Masson pursues research largely focused on delivering personalized medicine and her recent research focuses on the prediction of therapeutic responses and the development of new therapeutic agents for ovarian and prostate cancers. Mes-Masson is both a Fellow of the Canadian Academy of Health and a Fellow of the Royal Society of Canada.